Region Dalarna

The Hematology department at Region Dalarna is advancing treatment for blood cancers and solid tumors, focusing on innovative therapies and biomarker‑driven strategies.

• Evaluation of novel antibody‑drug combinations for relapsed or refractory multiple myeloma
• Biomarker‑guided treatment duration in chronic lymphocytic leukemia and small lymphocytic lymphoma
• Optimizing induction regimens for acute myeloid leukemia in adults
• Assessing adjuvant immunotherapy in high‑risk cutaneous malignant melanoma
• Targeted EGFR‑inhibitor sequencing for non‑small cell lung cancer
• Investigating aspirin adjunct therapy in PIK3CA‑mutated colorectal cancer

These studies aim to improve survival, reduce disease recurrence, and personalize therapy based on genetic and molecular profiles.

Researchers are exploring ways to lower cardiovascular risk and manage metabolic disorders, with an emphasis on heart failure and obesity‑related outcomes.

• Testing selatogrel for self‑administered acute myocardial infarction relief
• Evaluating maridebart cafraglutide on cardiovascular events in patients with atherosclerotic disease and obesity
• Spironolactone initiation trial in heart failure with preserved ejection fraction
• Combination of vicadrostat and empagliflozin to reduce heart failure hospitalizations in type 2 diabetes
• Metformin’s effect on growth of small abdominal aortic aneurysms
• Beta‑blocker use in chronic obstructive pulmonary disease patients without cardiovascular disease to prevent exacerbations

The goal is to demonstrate reduced cardiovascular morbidity, better heart‑failure outcomes, and safer management of obesity‑linked conditions.

The site’s pulmonary program targets chronic lung diseases and lung cancer, integrating pharmacologic and device‑based approaches.

• Assessing long‑term beta‑blocker therapy in chronic obstructive pulmonary disease
• Optimizing EGFR‑inhibitor sequences for EGFR‑mutated non‑small cell lung cancer
• Evaluating local antimicrobial agents for healing of diabetic foot ulcers with respiratory comorbidities

These investigations seek to improve lung function, reduce exacerbations, and enhance cancer treatment efficacy.

Clinical studies are addressing inflammatory skin conditions, aiming to refine biologic therapies and improve quality of life.

• Phase III trial of lebrikizumab for moderate‑to‑severe atopic dermatitis
• Comparative study of oral versus subcutaneous methotrexate in early rheumatoid arthritis
• Investigation of weight‑maintenance dosing of semaglutide in adolescents post‑obesity treatment

The focus is on confirming efficacy, safety, and long‑term disease control for patients with eczema, arthritis, and obesity‑related skin issues.

Trials at the clinic support women’s reproductive health, cervical cancer prevention, and post‑abortion contraception.

• Immediate intrauterine contraceptive insertion versus delayed placement after medical abortion
• Population‑level study of combined HPV vaccination and screening to accelerate elimination of HPV infection
• Outpatient versus inpatient induction of labour safety and effectiveness assessment

These projects aim to enhance contraceptive uptake, reduce cervical disease burden, and improve labor induction practices.

The orthopedic research stream investigates infection control and vascular health in joint and aortic procedures.

• Antibiotic‑impregnated bone graft trial to lower prosthetic joint infection rates
• Metformin evaluation for slowing growth of small abdominal aortic aneurysms
• Observational study of patients under active surveillance for small abdominal aortic aneurysms

Objectives include reducing postoperative infections, preventing aneurysm expansion, and informing surveillance guidelines.